Cosmc Double Nickase Plasmid (h): sc-409904-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Cosmc Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Cosmc Double Nickase Plasmid (h) and Cosmc Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting C1GALT1C1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Cosmc Antibody (H-10): sc-271829
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cosmc Double Nickase Plasmid (h) | sc-409904-NIC | 20 µg | $410.00 |
C1GALT1C1 encodes Cosmc, an endoplasmic reticulum–resident molecular chaperone required for the folding and stability of core 1 β1,3-galactosyltransferase (C1GALT1), thereby enabling biosynthesis of core 1 O-glycans. By supporting mucin-type O-glycosylation, Cosmc influences protein trafficking, cell–cell interactions, and lectin-mediated signaling that depend on properly elaborated O-glycan structures. Loss or dysfunction of Cosmc disrupts O-glycan extension and promotes accumulation of truncated O-glycans such as Tn and sialyl-Tn antigens, altering the glycoproteome and surface receptor behavior. Aberrant Cosmc-associated O-glycosylation patterns have been linked to immune recognition changes and malignant transformation contexts, making C1GALT1C1 a useful target for mechanistic glycobiology studies.
Cosmc Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the C1GALT1C1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within C1GALT1C1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt C1GALT1C1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of C1GALT1C1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.